STAGE T1C PROSTATE-CANCER - DEFINING THE APPROPRIATE STAGING EVALUATION AND THE ROLE FOR PELVIC LYMPHADENECTOMY

A good staging system should be able to accurately reflect the natural history of a malignant disease, to express the extent of the disease at the time of diagnosis, and stratify patients in prognostically dist inctive groups. The staging system for prostate cancer, as it is today , fails to fulfill these requirements. Approximately one third of the patients who undergo surgery for complete excision of prostate cancer in fact do not have a localize disease. The incidence of tumor at the inked margin may reach 30% for T1 stage and up to 60% for clinical T2b prostate cancer according to comparision with pathologic examination of resected specimen. Several concepts have been recently proposed as a means of improving the accuracy of the available staging system. In this paper, we review current aspects of clinical and pathological sta ging of prostate cancer, and the importance of these new concepts on t he early stages of prostate cancer.